Translating unique human immune responses
into superior medicines
At Memo Therapeutics AG we are developing best-in-class therapeutic antibodies based on natural immunity in elite responders to transform the lives of patients with viral infections and cancer.
Memo Therapeutics AG, an Ipsen company is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with viral infections.
Our lead program, potravitug, currently in Phase II development, is the most potent antibody ever tested in clinical trials to treat BK polyomavirus (“BKPyV”) infection in kidney transplant recipients. BKPyV infection can lead to nephropathy, loss of kidney function, as well as organ failure, rejection and death.
About us
Find out more about us and our mission to change the standard of care for patients with viral infections and cancer.
BKV
Our most advanced program, potravitug, focuses on BKPyV infection which can pose a serious threat to the health and wellbeing of kidney transplant recipients. Find out more about how we hope to offer a solution for patients who currently have no effective treatment alternative available to them.
About us
Find out more about us and our mission to change the standard of care for patients with viral infections and cancer.
BKV
Our most advanced program, potravitug, focuses on BKPyV infection which can pose a serious threat to the health and wellbeing of kidney transplant recipients. Find out more about how we hope to offer a solution for patients who currently have no effective treatment alternative available to them.
Oncology
We are mining antibody repertoires of tumor infiltrating B-cells from elite cancer patients to discover superior antibodies and targets to develop new medicines.
DROPZYLLA
Phase 2 for potravitug targeting BKV
Latest news
Latest publications
